TBI field-biomarker update: dried capillary plasma could simplify future EMS trial sampling

Evidence status: external analytical/clinical-methods publication; not an AIRCHILL study, not a cleared field diagnostic, and not evidence that respiratory cooling benefits traumatic brain injury.

What is new

A peer-reviewed study published 4 September 2026 evaluated a dried-plasma biosampling lateral-flow device for traumatic-brain-injury biomarkers. The device accepts approximately 50–70 µL capillary blood, separates plasma onto a dry strip and was tested with GFAP, UCH-L1, NfL and Tau. Dried-sample measurements correlated strongly with matched wet plasma in an archived geriatric TBI cohort, and a second adult TBI cohort showed proof-of-principle discrimination of CT-positive cranial lesions. Signal recovery declined with prolonged room-temperature or high-temperature storage, so this remains a sample-handling technology under evaluation rather than a validated diagnostic endpoint.

Why it matters for MedicalCooling

For any future AIRCHILL TBI or neurotrauma programme, one practical barrier is obtaining time-resolved neuroinjury biomarkers in ambulances, emergency departments and distributed trauma networks without adding a full venous-processing and cold-chain workflow. A validated dried-capillary format could eventually reduce that burden and make serial biomarker collection easier across prehospital and hospital phases.

Protocol decision: do not adopt the device as a clinical endpoint or eligibility test yet. Track it as an enabling sampling technology. If an AIRCHILL TBI feasibility protocol is developed, a nested methods substudy could compare capillary dried plasma with the laboratory reference matrix and preserve exact sampling times, storage temperature and elapsed storage time.

Source and evidence boundary

Kobeissy F, Elbayoumi E, Arja RD, et al. Evaluation of a novel high-capacity dry plasma biosampling-lateral flow device for the testing of traumatic brain injury protein biomarkers. Journal of Advanced Research. Published 4 September 2026. PMID 42697480. DOI 10.1016/j.jare.2026.09.003. PubMed record.

This update changes trial-operations intelligence only. It does not change AIRCHILL efficacy assumptions, TBI effect-size assumptions, regulatory claims or current patient-use status.